Broder; Cancer Act’s Special Authorities Don’t Give Director Immunity For NIH, HHS
In Brief: House, Senate Enact FY ’92 Budget Bills For NCI That Differ By $200 Million; Senate’s Is Higher
Bypass Budget Is Realistic, Defensible Plan, Broder Says
Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)
Tipping Resigned Forom ACS Following Volunteer Discontent
NSABP Sees Groups To Join Breast Cancer Prevention Trial
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup









